Restylane Contour
Q-Med AB · Decision date May 15, 2026
What did the FDA approve?
FDA records P140029/S057 as a supplement to PMA P140029, with the supplement type “Normal 180 Day Track No User Fee”. The recorded decision is approval, dated May 15, 2026.
FDA approval order statement
Approval for the post-approval study protocol to evaluate the safety of re-treatment with Restylane Contour in the treatment of temple hollowing
- Regulatory pathway
- PMA supplement
- Supplement type
- Normal 180 Day Track No User Fee
- Clinical specialty
- General, Plastic Surgery
- Decision date
- May 15, 2026
- FDA change category
- Postapproval Study Protocol
Regulatory record facts
- Identifier
- P140029/S057
- Regulatory pathway
- PMA supplement
- Applicant
- Q-Med AB
- Product code
- LMH
- Decision code
- APPR
- Decision date
- May 15, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Implant, dermal, for aesthetic use.
For the original device and its historical approval scope, see PMA P140029. Subsequent supplements may change the device or its indications.
FDA decision timeline
P140029 · Original PMA
Restylane Refyne, Restylane Defyne
P140029/S055 · Related supplement
Restylane Refyne, Restylane Defyne, Restylane Kysse and Restylane Contour
P140029/S054 · Related supplement
Restylane Contour
P140029/S056 · Related supplement
Restylane Refyne, Restylane Defyne, Restylane Kysse and Restylane Contour
P140029/S057 received
Application receipt date recorded by FDA.
P140029/S057 · FDA decision
Normal 180 Day Track No User Fee
P140029/S058 · Related supplement
Restylane Contour
Timeline entries are records held by MedtechLedger for P140029. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P140029
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Q-Med AB | PMA approval | Dec 9, 2016 | FDA | |
| Q-Med AB | PMA supplement | Sep 26, 2025 | FDA | |
Restylane ContourP140029/S054 | Q-Med AB | PMA supplement | Mar 20, 2026 | FDA |
| Q-Med AB | PMA supplement | Apr 14, 2026 | FDA | |
Restylane ContourP140029/S058 | Q-Med AB | PMA supplement | Sep 18, 2026 | FDA |
Explore the linked device profile
Other records with product code LMH
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Juvéderm Ultra XC; Juvéderm Ultra Plus XCP050047/S106 | Allergan | PMA supplement | Nov 4, 2026 | FDA |
Belotero Volume (+) LidocaineP250020/S004 | Merz North America, Inc. | PMA supplement | Nov 4, 2026 | FDA |
Belotero Intense (+) Lidocaine Dermal FillerP250016/S006 | Merz North America, Inc. | PMA supplement | Oct 21, 2026 | FDA |
| Prollenium Medical Technologies, Inc. | PMA supplement | Oct 14, 2026 | FDA | |
saypha ChiQP250021/S002 | Croma-Pharma GmbH | PMA supplement | Oct 8, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Q-Med AB
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- Seminariegatan 21, Uppsala, S-752 28
Sources and methodology
- Original FDA record: P140029/S057
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 21, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records





